Grow Your Pharma Business Digitally
Virtual Booth
Contact Supplier
Product Reset all filters
01 1Tukysa
Tucatinib
Pfizer Inc.
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 17
2022 Revenue in Millions : 0
Growth (%) : Acquired from Seagen
Portfolio PDF
Product Web Link
Digital Content
Website
Corporate PDF